ModerateSelective immunosuppressants×HMG-CoA reductase inhibitors (statins)
Updated · Methodology
Mechanism
Teriflunomide, the active metabolite of leflunomide, inhibits the transporters OATP1B1, OATP1B3 and breast cancer resistance protein (BCRP). With repeated dosing it raised rosuvastatin peak concentration 2.65-fold and total exposure (area under the curve, AUC) 2.51-fold (leflunomide summary of product characteristics, SmPC, European Medicines Agency, EMA). The leflunomide documents list simvastatin among the statins that are OATP substrates. With these drugs, they advise close monitoring for signs of excessive exposure (leflunomide SmPC, EMA; leflunomide label, US Food and Drug Administration, FDA). Simvastatin acid enters liver cells through OATP1B1, and simvastatin is a BCRP substrate. Inhibition of these transporters therefore raises simvastatin levels and with them the risk of myopathy and rhabdomyolysis (simvastatin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Leflunomide itself can cause myositis and rhabdomyolysis, often together with other immunosuppressants. Its active metabolite leaves the body slowly, with a half-life usually of 1–4 weeks (leflunomide SmPC, EMA).
Symptoms
The main risk is muscle damage: unexplained muscle pain, tenderness or weakness, sometimes with malaise or fever, and a rise in blood creatine kinase (CK) (simvastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; simvastatin label, US Food and Drug Administration, FDA). The severe form, rhabdomyolysis, can lead to acute kidney failure from myoglobin in the urine, and deaths have occurred very rarely (simvastatin SmPC, AEMPS). The risk of myopathy rises with the simvastatin dose: in clinical trials it was about 0.03% at 20 mg, 0.08% at 40 mg and 0.61% at 80 mg a day (simvastatin SmPC, AEMPS).
Management
The combination is allowed with caution: the leflunomide summary of product characteristics (SmPC) names simvastatin among the statins to be used with caution together with leflunomide (leflunomide SmPC, European Medicines Agency, EMA). Monitor the patient closely for signs and symptoms of excessive simvastatin exposure, that is, muscle symptoms, and consider reducing the simvastatin dose (leflunomide SmPC, EMA; leflunomide label, US Food and Drug Administration, FDA). With drugs that inhibit the transporter BCRP, the Spanish simvastatin SmPC advises considering a simvastatin dose adjustment, depending on the prescribed dose. Patients who take simvastatin 80 mg and need an interacting drug should switch to a lower simvastatin dose or to another statin with less potential for interactions (simvastatin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Warn the patient about the risk of myopathy and ask them to report any unexplained muscle pain, tenderness or weakness promptly (simvastatin SmPC, AEMPS; simvastatin label, FDA). If muscle symptoms appear, measure creatine kinase (CK) (simvastatin SmPC, AEMPS; leflunomide SmPC, EMA). Stop simvastatin if CK is more than 5 times the upper limit of normal without strenuous exercise, or if myopathy is suspected for any other reason (simvastatin SmPC, AEMPS). If myositis or rhabdomyolysis develops, also stop leflunomide and start the washout procedure: colestyramine 8 g three times a day or activated charcoal powder 50 g four times a day, usually for 11 days (leflunomide SmPC, EMA). The leflunomide documents set a mandatory dose ceiling only for rosuvastatin, 10 mg a day (leflunomide SmPC, EMA; leflunomide label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Zocor (simvastatin) tablets – Prescribing Information (2025)– FDA, DailyMed SPL, Organon, sections 2.5, 4, 5.1 and 7.1
- EMA: Ficha técnica: Leflunomida, Arava (EU/1/99/118), secciones 4.4 y 4.5 (2026)– EMA, SmPC Arava 10 mg comprimidos recubiertos con película, EU/1/99/118, texto en CIMA nº registro 99118003, consultado 19.10.2026, sin fecha de revisión en CIMA, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Leflunomida Normon 10 mg (nº registro 74343), sección 4.5 (2025)– AEMPS, CIMA, nº registro 74343 (Leflunomida Normon 10 mg comprimidos recubiertos con película EFG), revisión 10/2025, sección 4.5
- AEMPS: Ficha técnica: Simvastatina, Zocor 10 mg (nº registro 58845), sección 4.4 (2026)– AEMPS, CIMA, nº registro 58845 (Zocor 10 mg comprimidos recubiertos con película, Organon Salud), revisión 06/2026, secciones 4.2, 4.4, 4.5 y 5.2
- FDA: Arava (leflunomide) prescribing information (2025)– FDA, DailyMed setid 320f63f2-fac3-4aee-aff8-85724e00ef52 (Sanofi-Aventis U.S.), versión 27, vigente desde 04.06.2025, sección 7